[Efficacy and safety of basiliximab in gastrointestinal chronic graft-versus-host disease].

X L Zhu、J Z Wang、H X Fu、Z L Xu、Y Y Chen、X D Mo、X H Zhang、L P Xu

2026PubMed被引 1开放获取

摘要

Basiliximab may be used to treat GI-cGVHD, with hematologic and infection-related adverse event rates comparable to those of other systemic immunosuppressants. These findings suggest a potential therapeutic option for GI-cGVHD; however, larger prospective studies are needed to further evaluate its safety.

引用本文（GB/T 7714）

X L Zhu, J Z Wang, H X Fu, 等. [Efficacy and safety of basiliximab in gastrointestinal chronic graft-versus-host disease].[J]. PubMed, 2026.

引文网络

参考文献与被引分析加载中…

DOI：https://doi.org/10.3760/cma.j.cn121090-20250630-00306

本站仅收录题录与摘要供学习参考，全文版权归属出版方；如有侵权请联系我们删除。